Extracellular volume and aldosterone interaction in chronic kidney disease

Blood Purification

Volumn 27, Issue 1, 2009, Pages 92-98

  Klemmer, Philip J ^a   Bomback, Andrew S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Bioimpedance; Chronic kidney disease; Extracellular volume

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG SAFETY; EXTRACELLULAR FLUID; EXTRACELLULAR SPACE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERVOLEMIA; IMPEDANCE; KIDNEY FIBROSIS; KIDNEY FUNCTION; METABOLIC SYNDROME X; NEPHRITIS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; ULTRAFILTRATION; VASCULAR FIBROSIS; VASCULITIS;

ALDOSTERONE; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; EXTRACELLULAR FLUID; FIBROSIS; HUMANS; INFLAMMATION; KIDNEY DISEASES; RECEPTORS, MINERALOCORTICOID;

EID: 58849115865     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167016     Document Type: Conference Paper

References (52)

1. National Institute of Diabetes and Digestive and Kidney Diseases: US Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, 2007.
2. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126.
3. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-1068.
4. Fiebeler A, Muller DN, Shagdarsuren E, Luft FC: Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr Opin Nephrol Hypertens 2007;16:134-142.
5. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-1800.
6. Remuzzi G, Cattaneo D, Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008;19:1459-1462.
7. Joffe HV, Adler GK: Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005;10:31-37.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
10. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008;51:199-211.
11. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006;1:256-262.
12. Bianchi S, Bigazzi R, Campese VM: Longterm effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006;70:2116-2123.
13. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-951.
14. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004;27:303-310.
15. Young MJ: Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 2008;17:174-180.
16. Stier CT Jr, Rocha R, Chander PN: Effect of aldosterone and MR blockade on the brain and the kidney. Heart Fail Rev 2005;10:53-62.
17. Rudolph AE, Rocha R, McMahon EG: Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol 2004;217:229-238.
18. Ponda MP, Hostetter TH: Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 2006;1:668-677.
19. Zhu F, Leonard EF, Levin NW: Extracellular fluid redistribution during hemodialysis: bioimpedance measurement and model. Physiol Meas 2008;29:S491-S501.
20. Selye H, Hall CE, Rowley EM: Malignant hypertension produced by treatment with deoxycorticosterone acetate and sodium chloride. Can Med Assoc J 1943;6:88-92.
21. Guyton AC: Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension 1992;19:I2-I8.
22. Oliver WJ, Cohen EL, Neel JV: Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a 'nosalt' culture. Circulation 1975;52:146-151.
23. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Bühler FR: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-449.
24. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878.
25. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-492.
26. Rump LC: Secondary rise of albuminuria under AT1-receptor blockade - What is the potential role of aldosterone escape? Nephrol Dial Transplant 2007;22:5-8.
27. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002;40:28-33.
28. Conn JW, Knopf RF, Nesbit RM: Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964;107:159-172.
29. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248.
30. Peters JP: Body Water: The Exchange of Fluids in Man. Springfield, Thomas, 1935.
31. Schrier RW: Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006;119:S47-S53.
32. Relman AS, Schwartz WB: The effect of DOCA on electrolyte balance in normal man and its relation to sodium chloride intake. Yale J Biol Med 1952;24:540-558.
33. Charra B: Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int 2007;11:21-31.
34. Olgaard K, Madsen S, Ladefoged J, Regeur L: Plasma aldosterone during extracellular fluid volume expansion in patients on regular haemodialysis. Eur J Clin Invest 1977;7:61-66.
35. Mitch WE, Wilcox CS: Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med 1982;72:536-550.
36. Zhu F, Kuhlmann MK, Kaysen GA, Sarkar S, Kaitwatcharachai C, Khilnani R, Stevens L, Leonard EF, Wang J, Heymsfield S, Levin NW: Segment-specific resistivity improves body fluid volume estimates from bioimpedance spectroscopy in hemodialysis patients. J Appl Physiol 2006;100:717-724.
37. Alvarez-Lara MA, Martin-Malo A, Espinosa M, Rodriguez-Benot A, Aljama P: Blood pressure and body water distribution in chronic renal failure patients. Nephrol Dial Transplant 2001;16(suppl 1):94-97.
38. Katzarski KS, Divino Filho JC, Bergstrom J: Extracellular volume changes and blood pressure levels in hemodialysis patients. Hemodial Int 2003;7:135-142.
39. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van LF, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
40. Kramer BK, Ress KM, Ulshofer TM, Risler T: The renin-angiotensin- aldosterone system during haemodialysis with acetate or bicarbonate at different dialysate sodium concentrations. Nephrol Dial Transplant 1987;2:531-536.
41. Kohagura K, Higashiuesato Y, Ishiki T, Yoshi S, Ohya Y, Iseki K, Takishita S: Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival. Hypertens Res 2006;29:597-604.
42. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999;12:867-873.
43. Vogt B, Bochud M, Burnier M: The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol 2007;27:529-537.
44. Krug AW, Ehrhart-Bornstein M: Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008;51:1252-1258.
45. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98-101.
46. Epstein M, Sancho J, Perez G, Haber E, Re R, Loutzenhiser R: Volume as a determinant of plasma aldosterone in anephric man. J Clin Endocrinol Metab 1978;46:309-316.
47. Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J: High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008;117:224-230.
48. Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM: Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005;16:474-481.
49. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:2359-2363.
50. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL: Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003;18:2364-2368.
51. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005;46:94-101.
52. Goodfriend TL, Ball DL, Egan BM, et al: Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004;43:358-363.